EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Hypoparathyroidism - Pipeline Review, H1 2015

  • ID: 3330528
  • Report
  • June 2015
  • 43 pages
  • Global Markets Direct
1 of 4
Hypoparathyroidism - Pipeline Review, H1 2015

Summary

This, ‘Hypoparathyroidism - Pipeline Review, H1 2015’, provides an overview of the Hypoparathyroidism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoparathyroidism and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypoparathyroidism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypoparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypoparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hypoparathyroidism Overview
Therapeutics Development
Pipeline Products for Hypoparathyroidism - Overview
Pipeline Products for Hypoparathyroidism - Comparative Analysis
Hypoparathyroidism - Therapeutics under Development by Companies
Hypoparathyroidism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hypoparathyroidism - Products under Development by Companies
Hypoparathyroidism - Companies Involved in Therapeutics Development
Chugai Pharmaceutical Co., Ltd.
Rhein-Minapharm Biogenetics SAE
Shire Plc
Hypoparathyroidism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Eu-232 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
parathyroid hormone (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize PTH-R for Hypoparathyroidism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypoparathyroidism - Recent Pipeline Updates
Hypoparathyroidism - Product Development Milestones
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism
Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA)) in Hypoparathyroidism
Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015
Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism
Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application
Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara® for Hypoparathyroidism
Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism
Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12 - PDUFA Date of October 24 Remains Unchanged
Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism
Jan 03, 2014: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara in Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hypoparathyroidism, H1 2015
Number of Products under Development for Hypoparathyroidism - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015
Hypoparathyroidism - Pipeline by Rhein-Minapharm Biogenetics SAE, H1 2015
Hypoparathyroidism - Pipeline by Shire Plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hypoparathyroidism Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Hypoparathyroidism, H1 2015
Number of Products under Development for Hypoparathyroidism - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Chugai Pharmaceutical Co., Ltd.
Rhein-Minapharm Biogenetics SAE
Shire Plc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll